Ruxolitinib for childhood ALL in Poland (Rux-cALL-Pol 2020 trial) - Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway.

Status

Not yet recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518316-39-00

Acronym

Rux-cALL-Pol 2020

Enrollment

Registered

2024-11-18

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphoblastic leukemia

Brief summary

Proportion of patients with MRD(-) at TP2.

Detailed description

Frequency and grading of adverse events in Consol. IB ext. phase (number, percentage, number per patient-days, number per each grade of significance)., Incidence of treatment-related adverse and severe adverse events.

Interventions

DRUGMETHOTREXATE DISODIUM

DRUGCYTARABINE

DRUGIFOSFAMIDE

DRUGRUXOLITINIB

DRUGVINDESINE SULFATE

DRUGVINCRISTINE SULFATE

DRUGETOPOSIDE

DRUGDEXAMETHASONE PHOSPHATE

DRUGCYCLOPHOSPHAMIDE

DRUGMETHOTREXATE

DRUGASPARAGINASE

DRUGDAUNORUBICIN

DRUGPEGASPARGASE

DRUGDEXAMETHASONE

DRUGMERCAPTOPURINE

DRUGDOXORUBICIN HYDROCHLORIDE

DRUGTIOGUANINE

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Proportion of patients with MRD(-) at TP2.	—

Secondary

Measure	Time frame
Frequency and grading of adverse events in Consol. IB ext. phase (number, percentage, number per patient-days, number per each grade of significance)., Incidence of treatment-related adverse and severe adverse events.	—

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026